General Information of the Protein
Protein ID
PT00900
Protein Name
Neutrophil collagenase
Secondarily
Protein Name
Matrix metalloproteinase-8
PMNL collagenase
Gene Name
MMP8
Secondarily
Gene Name
CLG1
Sequence
MFSLKTLPFLLLLHVQISKAFPVSSKEKNTKTVQDYLEKFYQLPSNQYQSTRKNGTNVIVEKLKEMQRFFGLNVTGKPNEETLDMMKKPRCGVPDSGGFMLTPGNPKWERTNLTYRIRNYTPQLSEAEVERAIKDAFELWSVASPLIFTRISQGEADINIAFYQRDHGDNSPFDGPNGILAHAFQPGQGIGGDAHFDAEETWTNTSANYNLFLVAAHEFGHSLGLAHSSDPGALMYPNYAFRETSNYSLPQDDIDGIQAIYGLSSNPIQPTGPSTPKPCDPSLTFDAITTLRGEILFFKDRYFWRRHPQLQRVEMNFISLFWPSLPTGIQAAYEDFDRDLIFLFKGNQYWALSGYDILQGYPKDISNYGFPSSVQAIDAAVFYRSKTYFFVNDQFWRYDNQRQFMEPGYPKSISGAFPGIESKVDAVFQQEHFFHVFSGPRYYAFDLIAQRVTRVARGNKWLNCRYG
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Protease
>
Metallo protease
>
Metallo protease MAM clan
>
Metallo protease M10A subfamily
Function
Can degrade fibrillar type I, II, and III collagens.
    Show/Hide
Uniprot ID
Primary ID:
P22894

Secondarily ID:
Q45F99
    Show/Hide
Ensembl ID
ENSG00000118113
HGNC ID
HGNC:7175
Subcellular Location
Cytoplasmic granule
Secreted
Extracellular space
Extracellular matrix
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000011 , CHO
Compound ID Compound Name Compound Formula
CP0199497
US9206139, 2
   Show/Hide
C19H22F3N3O3
 1
1
IC50 < 5.1 nM
   TI
   LI
   LO
   TS
CP0069428
US9206139, 1
   Show/Hide
C18H20F3N3O3
 1
1
IC50 = 17.9 nM
   TI
   LI
   LO
   TS
CP0069431
US9206139, 5
   Show/Hide
C19H22F3N3O3
 1
1
IC50 = 54 nM
   TI
   LI
   LO
   TS
CP0118960
US9206139, 3
   Show/Hide
C20H22F3N3O3
 1
1
IC50 = 804 nM
   TI
   LI
   LO
   TS
CP0069429
US9206139, 4
   Show/Hide
C20H24F3N3O3
 1
1
IC50 = 5220 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0099232
5-[3-fluoro-4-[(4-oxo-3,5,6,7-tetrahydrocyclopenta[d]pyrimidin-2-yl)sulfanylmethyl]phenyl]-N-[(2S)-3-methyl-1-(methylamino)-1-oxobutan-2-yl]furan-2-carboxamide
   Show/Hide
C25H27FN4O4S
 1
1 IC50 > 5000 nM
CP0117835
5-[3-fluoro-4-[(4-oxo-3,5,6,7-tetrahydrocyclopenta[d]pyrimidin-2-yl)sulfanylmethyl]phenyl]-N-[(2R)-3-methyl-1-(methylamino)-1-oxobutan-2-yl]furan-2-carboxamide
   Show/Hide
C25H27FN4O4S
 1
1 IC50 > 5000 nM
CP0159081
N-[(1R)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[3-fluoro-4-[(4-oxo-3,5,6,7-tetrahydrocyclopenta[d]pyrimidin-2-yl)sulfanylmethyl]phenyl]furan-2-carboxamide
   Show/Hide
C28H31FN4O4S
 1
1 IC50 > 5000 nM
CP0228998
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[3-fluoro-4-[(4-oxo-3,5,6,7-tetrahydrocyclopenta[d]pyrimidin-2-yl)sulfanylmethyl]phenyl]furan-2-carboxamide
   Show/Hide
C28H31FN4O4S
 1
1 IC50 > 5000 nM
CP0038814
2-[(4-chlorobenzyl)thio]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one
   Show/Hide
C14H13ClN2OS
 1
1 IC50 > 100000 nM
Clinical Information about the Protein
Target 1 ( Matrix metalloproteinase-8 (MMP-8) )
Target Type Clinical trial Target
Disease 3 Target-related Diseases  3
1 Rheumatoid arthritis [ICD-11: FA20]
2 Corneal ulcer [ICD-11: 9A76]
3 Multiple sclerosis [ICD-11: 8A40]
Clinical Trial Drug(s) 1 Clinical Trial Drug  1
1 CIPEMASTAT Phase 3
Rheumatoid arthritis
Discontinued Drug(s) 2 Discontinued Drugs  2
1 GM6001 Discontinued in Phase 2
Corneal ulcer
2 BB-1101 Terminated
Multiple sclerosis